Korean Market
EXCH
AprilBio
★★★

AprilBio Largest Shareholder Change Finalized, Control Transferred to IMM Consortium with Large Capital Increase Raising Dilution Concerns

 
EXCH
AprilBio
★

AprilBio Completes 50 Billion Won Third-Party Placement with Management Change Contract

 
EXCH
AprilBio
★★

AprilBio completes 141.8 billion won third-party allocation capital increase, issuing 17.5% new shares, raising dilution concerns for existing shareholders

 
EXCH
AprilBio
★

AprilBio Completes 154.9 Billion Won Third-Party Allocation Capital Raise with Management Change Implications

 
MATR
AprilBio
★

AprilBio Amends Paid-In Capital Increase Report for Convertible Preferred Shares, Changes Third-Party Allottee to SPC

 
MATR
AprilBio
★

AprilBio Amends Rights Issue Disclosure – Changes Third-Party Allottee to SPC, Terms Unchanged

 
EXCH
AprilBio
★

AprilBio Amends Joint Investment Agreement Party in Management Change with TKG Huchems; No Change to Core Financial Terms

 
EXCH
AprilBio
★

AprilBio Signs Technology Introduction Agreement with Curigin for Dual-Target siRNA Platform Metabolic Disease Therapeutics

 
OWNR
AprilBio
★

AprilBio's Largest Shareholder Sanghoon Cha Sells 7.56% Stake at Discount, Diluting Control - New Investors Include IMM Asset Management and TKG Huchems

 
EXCH
AprilBio
★

AprilBio Management Change, Issuance of 150 Billion Won Convertible Preferred Shares to TKG Huchems… Dilution of 14.9%

 
EXCH
AprilBio
★

AprilBio Denies Taekwang Industrial Acquisition Rumor, Confirms Management Change Contracts with TKG Huchems and IMM

 
EXCH
AprilBio
★

AprilBio Issues 150 Billion Won in Third-Party Allotment for Management Transfer, Diluting Shares by 15% but Gaining Strategic Partner TKG Huchems

 
MATR
AprilBio
★★

AprilBio Raises 155 Billion KRW via Convertible Preference Shares, Diluting Existing Shareholders by Approximately 15%

 
MATR
AprilBio
★

AprilBio Issures 50 Billion Won Convertible Preferred Shares for R&D, 5.22% Dilution Mitigated by Premium Pricing and Lock-Up

 
MATR
AprilBio
★

AprilBio Decides 141.8 Billion Won Third-Party Allotment for R&D Funding, Dilution of 17.5% and Change in Control